Bank earnings loom large; CPI ahead; Nvidia’s China chip - what’s moving markets
SAN DIEGO—Michael J. Rider, the Global General Counsel of ResMed Inc . (NYSE:RMD), a $36.2 billion medical equipment company currently trading near its 52-week high at $246.78, recently executed a sale of company stock valued at approximately $9,994, according to a filing with the Securities and Exchange Commission. The transaction, which took place on June 2, involved the sale of 41 shares at a price of $243.78 each. This sale was conducted under a pre-established Rule 10b5-1 trading plan, which Rider adopted on February 28, 2025. According to InvestingPro, ResMed maintains a strong financial health score of "GREAT" with robust liquidity metrics, including a current ratio of 3.41.
Following this transaction, Rider’s direct ownership of ResMed’s common stock stands at 8,870 shares. Additionally, on the same day, Rider disposed of 267.244 shares back to the issuer for tax withholding purposes, related to the vesting of Restricted Stock Units granted in 2023. This transaction was valued at approximately $65,418, with shares priced at $244.79 each. For deeper insights into ResMed’s valuation and 12+ additional exclusive ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
The footnotes in the filing detail that Rider’s remaining shares include 64.6438 shares acquired through the ResMed Employee Stock Purchase Plan on April 30, 2025.
In other recent news, ResMed’s financial performance and analyst evaluations have drawn significant attention. ResMed’s third-quarter results met expectations, prompting Citi analysts to raise the stock’s price target to AUD45.00 from AUD44.00 while maintaining a Buy rating. This adjustment reflects an anticipated improvement in earnings per share from fiscal years 2025 to 2027. UBS also reaffirmed a Buy rating for ResMed, setting the price target at $285.00, following promising results from Apnimed’s Phase 3 clinical trial for a new sleep apnea treatment. Meanwhile, Stifel maintained a Hold rating with a $240.00 price target, noting that device sales fell short of projections, though mask sales exceeded expectations.
RBC Capital Markets increased ResMed’s price target to $255.00 from $247.00, maintaining a Sector Perform rating. This adjustment came after ResMed’s fiscal third-quarter results showed robust growth in revenue and earnings, alongside a significant announcement about the company’s products being largely exempt from U.S. import tariffs. Despite these positive updates, analysts continue to monitor potential impacts from GLP-1 medications and the uncertainty of Philips’ return to the U.S. market by 2027. ResMed’s strong balance sheet, with net cash and substantial free cash flow generation, remains a point of confidence for analysts. Investors are likely to keep a close watch on upcoming developments, including Apnimed’s FDA submission and the detailed trial data release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.